Jiangxi Institute of Biological Products (HKSE:06915) WACC %:10.84% (As of Sep. 10, 2026) — 188% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06915 Jiangxi Institute of Biological Products Inc HKSE:06915
23 GF Score
Price HK$16.72
! 3 Warning Signs
View Full Analysis

What is Jiangxi Institute of Biological Products WACC %?

Jiangxi Institute of Biological Products HKSE:06915 +1.33% 23 WACC % is 10.84% as of Sep. 10, 2026, which is 188% above its 10-year median of 3.76. GuruFocus rates HKSE:06915 with a GF Score™ of 23/100. The stock has 3 warning signs investors should review. Among 1,020 Drug Manufacturers companies, Jiangxi Institute of Biological Products ranks worse than 69.12% on this metric.

As of today (2026-09-10), Jiangxi Institute of Biological Products's weighted average cost of capital is 10.84%%. Jiangxi Institute of Biological Products's ROIC % is 24.31% (calculated using TTM income statement data). Jiangxi Institute of Biological Products generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.

*Note: The beta of this company cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.

For a comprehensive WACC calculation, please access the WACC Calculator.


Jiangxi Institute of Biological Products  (HKSE:06915) WACC % Explanation

Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Jiangxi Institute of Biological Products's weighted average cost of capital is 10.84%%. Jiangxi Institute of Biological Products's ROIC % is 24.31% (calculated using TTM income statement data). Jiangxi Institute of Biological Products generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.

*Note: The beta of this company cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.


Be Aware

1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year annual average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.

2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.

3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.

4. GuruFocus uses the latest annual Interest Expense divided by the latest one-year annual average debt to get the simplified cost of debt.


Related Terms

Jiangxi Institute of Biological Products WACC % Historical Data

* Premium members only.

The historical data trend for Jiangxi Institute of Biological Products's WACC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jiangxi Institute of Biological Products WACC % Chart

Jiangxi Institute of Biological Products Annual Data
Trend Dec23 Dec24 Dec25
WACC %
2.76 16.30 3.76

Jiangxi Institute of Biological Products Semi-Annual Data
Dec23 Dec24 Dec25
WACC % 2.76 16.30 3.76

HKSE:06915 vs LLY, JNJ, ABBV: WACC % Comparison

For the Drug Manufacturers - General subindustry, Jiangxi Institute of Biological Products's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jiangxi Institute of Biological Products WACC % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jiangxi Institute of Biological Products's WACC % distribution charts can be found below:

* The bar in red indicates where Jiangxi Institute of Biological Products's WACC % falls into.


HKSE:06915
23GF Score
Jiangxi Institute of Biological Products Inc HKSE:06915
WACC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jiangxi Institute of Biological Products WACC % Calculation

The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.

WACC=E/(E + D)*Cost of Equity+D/(E + D)*Cost of Debt*(1 - Tax Rate)

1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, Jiangxi Institute of Biological Products's market capitalization (E) is HK$5156.070 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year annual average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Dec. 2025, Jiangxi Institute of Biological Products's latest one-year annual average Book Value of Debt (D) is HK$0.877 Mil.
a) weight of equity = E / (E + D) = 5156.070 / (5156.070 + 0.877) = 0.9998
b) weight of debt = D / (E + D) = 0.877 / (5156.070 + 0.877) = 0.0002

2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 4.841%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. Jiangxi Institute of Biological Products's beta cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 4.841% + 1 * 6% = 10.841%

3. Cost of Debt:
GuruFocus uses latest annual Interest Expense divided by the latest one-year annual average debt to get the simplified cost of debt.
As of Dec. 2025, Jiangxi Institute of Biological Products's interest expense (positive number) was HK$0.038 Mil. Its total Book Value of Debt (D) is HK$0.877 Mil.
Cost of Debt = 0.038 / 0.877 = 4.333%.

4. Multiply by one minus annual Tax Rate:
GuruFocus uses the most recent annual Tax Expense divided by the most recent annual Pre-Tax Income to calculate the tax rate. The calculated annual tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated annual Tax Rate = 15.983 / 120.704 = 13.24%.

Jiangxi Institute of Biological Products's Weighted Average Cost Of Capital (WACC) for Today is calculated as:

WACC=E / (E + D)*Cost of Equity+D / (E + D)*Cost of Debt*(1 - Tax Rate)
=0.9998*10.841%+0.0002*4.333%*(1 - 13.24%)
=10.84%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about WACC % →
What does a WACC % of 10.84% mean?
Jiangxi Institute of Biological Products (HKSE:06915) has a WACC % of 10.84% as of Sep. 10, 2026. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Jiangxi Institute of Biological Products and its competitors. This is 188% above median its historical median of 3.76. Over the past decade, Jiangxi Institute of Biological Products' WACC % has ranged from 2.76 to 16.30. According to the industry distribution chart, Jiangxi Institute of Biological Products ranks #705 out of 1020 companies in the Drug Manufacturers industry, placing it in the top 69.1%.
Is Jiangxi Institute of Biological Products' WACC % too high?
Jiangxi Institute of Biological Products' current WACC % of 10.84% is 188% above median its 10-year median of 3.76. Over the past 10 years, this metric has ranged from a low of 2.76 to a high of 16.30. The Drug Manufacturers industry median WACC % is 9.02. Jiangxi Institute of Biological Products' value of 10.84% is 20.2% above this industry median. Based on the distribution chart, Jiangxi Institute of Biological Products ranks #705 out of 1020 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Jiangxi Institute of Biological Products has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Jiangxi Institute of Biological Products' WACC % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Jiangxi Institute of Biological Products ranks #705 out of 1020 companies for WACC %. This places Jiangxi Institute of Biological Products in the lower half of its industry. The industry median WACC % is 9.02. Jiangxi Institute of Biological Products' value of 10.84% is 20.2% above this benchmark. Historically, Jiangxi Institute of Biological Products' own WACC % has ranged from 2.76 to 16.30 over the past decade. While the company's 10-year median is 3.76 vs. the industry median of 9.02, Jiangxi Institute of Biological Products has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good WACC % for a Drug Manufacturers company?
The median WACC % among Drug Manufacturers companies is 9.02, based on 1,020 companies in the industry. Companies in the top quartile (top 25%) have a WACC % significantly above this median, while those in the bottom quartile fall well below. However, WACC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangxi Institute of Biological Products's current WACC % of 10.84% is 20.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high WACC % mean?
A high WACC % can signal that a stock is expensive relative to its fundamentals. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Jiangxi Institute of Biological Products and its competitors. For the Drug Manufacturers industry, the median WACC % is 9.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangxi Institute of Biological Products's current WACC % is 10.84%, which is 188% above median its own 10-year median of 3.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangxi Institute of Biological Products stock overvalued right now?
Jiangxi Institute of Biological Products (HKSE:06915) has a current WACC % of 10.84%. The current WACC % is 10.84%, which is 188% above median its 10-year median of 3.76 and 20.2% above the Drug Manufacturers industry median of 9.02. Jiangxi Institute of Biological Products' overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is WACC % calculated?
WACC % is calculated from a company's financial statements. For Jiangxi Institute of Biological Products (HKSE:06915), the current WACC % is 10.84% as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Jiangxi Institute of Biological Products Business Description

Address No. 198 Huoju Avenue, Jinggangshan Economic and Technological Development Zone, Jiangxi Province, Ji’an, CHN
Jiangxi Institute of Biological Products Inc is principally engaged in the business of research and development, and production and sale of human tetanus antitoxin. It operates as the provider and exporter of Human TAT in China and an antiserum platform company. Its products include biological products containing immunoglobulins or immunoglobulin F(ab')2 fragments, which are used in medical applications such as tetanus, snakebite envenoming, and rabies treatment. The majority of the company's revenue is derived from the sale of Human Tetanus Antitoxin in the Chinese mainland.
23GF Score

Get the complete analysis for HKSE:06915

WACC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$16.72
Price